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Lawrence B. Schwartz, M.D., Ph.D., Lanny J. Rosenwasser, M.D., Johannes Ring, M.D., Ph.D.,
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and Gerald J. Gleich, M.D., for the Mepolizumab HES Study Group*

A BS T R AC T
BACKGROUND

The hypereosinophilic syndrome is a group of diseases characterized by persistent
blood eosinophilia, defined as more than 1500 cells per microliter with end-organ
involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.
METHODS

We conducted an international, randomized, double-blind, placebo-controlled trial
evaluating the safety and efficacy of an anti–interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome. Patients were negative
for the FIP1L1–PDGFRA fusion gene and required prednisone monotherapy, 20 to 60 mg
per day, to maintain a stable clinical status and a blood eosinophil count of less than
1000 per microliter. Patients received either intravenous mepolizumab or placebo while
the prednisone dose was tapered. The primary end point was the reduction of the
prednisone dose to 10 mg or less per day for 8 or more consecutive weeks.
RESULTS

The primary end point was reached in 84% of patients in the mepolizumab group, as
compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P<0.001) with no increase in clinical activity of
the hypereosinophilic syndrome. A blood eosinophil count of less than 600 per microliter for 8 or more consecutive weeks was achieved in 95% of patients receiving
mepolizumab, as compared with 45% of patients receiving placebo (hazard ratio,
3.53; 95% CI, 1.94 to 6.45; P<0.001). Serious adverse events occurred in seven patients receiving mepolizumab (14 events, including one death; mean [±SD] duration
of exposure, 6.7±1.9 months) and in five patients receiving placebo (7 events; mean
duration of exposure, 4.3±2.6 months).
CONCLUSIONS
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Our study shows that treatment with mepolizumab, an agent designed to target
eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1–
PDGFRA who have the hypereosinophilic syndrome. (ClinicalTrials.gov number,
NCT00086658.)
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T

he hypereosinophilic syndrome
consists of several heterogeneous disorders
characterized by sustained blood eosinophilia and eosinophil-related end-organ damage,
with no identifiable cause, such as parasitic infection.1 The objective of treatment is long-term reduction of blood and tissue eosinophil levels to
prevent end-organ damage and thromboembolic
events. Except for the myeloproliferative variant of
the hypereosinophilic syndrome (associated with
the Fip1-like 1–platelet-derived growth factor receptor α fusion gene [FIP1L1–PDGFRA]), for which
imatinib mesylate is considered first-line therapy,
current management is based on long-term systemic corticosteroids.1-4
Eosinophil development from hematopoietic
progenitors is regulated mainly by interleukin-5,5
which has a selective role in eosinophil maturation, differentiation, mobilization, activation, and
survival.5-11 Since interleukin-5 appears to contribute to the pathogenesis of some phenotypes
of the hypereosinophilic syndrome,12 interleukin-5
inhibition is a logical therapeutic target for this
disease.
Mepolizumab is a fully humanized, anti–interleukin-5 monoclonal immunoglobulin G1 antibody with a half-life of approximately 19 days; it
does not fix complement.13,14 By binding to free
interleukin-5 with high affinity and specificity, it
prevents interleukin-5 from associating with the
interleukin-5 receptor α chain on the surface of
eosinophils and their progenitors. In preliminary
studies of healthy volunteers and patients with
atopy, mepolizumab had few side effects and lowered blood eosinophil levels.15-19 Subsequent studies suggested that mepolizumab may have clinical value in patients with the hypereosinophilic
syndrome.20-22
After these initial reports, we conducted a randomized, double-blind, placebo-controlled trial of
targeted therapy for patients with the hypereosinophilic syndrome. Our aim was to evaluate the
effects of mepolizumab on corticosteroid sparing
and the maintenance of clinical stability in patients with disease that requires control with the
use of corticosteroids.
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≥6 months and eosinophilia-related organ involvement or dysfunction, with no identifiable secondary cause of eosinophilia23). All patients were negative for the FIP1L1–PDGFRA fusion gene, on the
basis of in situ hybridization to detect deletion of
the cysteine-rich hydrophobic domain 2 (CHIC2)
locus, a FIP1L1–PDGFRA surrogate, in peripheralblood mononuclear cells.24
STUDY DESIGN

Our randomized, double-blind, placebo-controlled,
parallel-group, multicenter study, involved 26 sites
in the United States, Canada, Belgium, France,
Germany, Italy, Switzerland, and Australia. It was
conducted from March 2004 through March 2006.
After screening, patients entered a run-in period
of up to 6 weeks, during which noncorticosteroid
medications for the hypereosinophilic syndrome
were discontinued and prednisone monotherapy
(20 to 60 mg per day for at least 1 week) was administered to achieve a stable clinical status (defined as no new or worsening clinical signs or
symptoms of the hypereosinophilic syndrome and
a blood eosinophil count of <1000 per microliter).
Methylprednisolone, prednisolone, or triamcinolone could be used at a dose equivalent to that of
prednisone, at the investigator’s discretion. (See
Supplementary Appendix 1, available with the full
text of this article at www.nejm.org, for details on
blinding, exclusion criteria, eosinophil-derived
neurotoxin enzyme-linked immunosorbent assay
methods, and corticosteroid conversion.)
Patients whose clinical symptoms were stabilized with the use of prednisone monotherapy (20
to 60 mg per day) or the equivalent were randomly
assigned in a one-to-one ratio to receive intravenous infusions of either mepolizumab (750 mg)
or placebo (saline) and were stratified according
to the daily prednisone dose (≤30 mg or >30 mg)
at baseline. Mepolizumab or placebo was administered every 4 weeks during a 36-week period (final infusion at week 32). The prednisone dose was
tapered, starting at week 1, using a predefined
algorithm based on eosinophil counts and clinical manifestations of the hypereosinophilic syndrome (Fig. 1A). Week 32 was the last visit at
which a taper dose could be prescribed; the patient then took that dose until week 36, the end
Me thods
of the treatment period. This approach to corticoSTUDY POPULATION
steroid dosing was used to maintain control by
The study patients were 18 to 85 years of age and allowing for corticosteroid rescue therapy for dishad the hypereosinophilic syndrome (defined as ease flares.
a blood eosinophil count >1500 per microliter for
Patients who completed the trial or withdrew
1216
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A
Mepolizumab (750 mg) or placebo (saline), intravenously, every 4 wk through wk 32

Instructions for Tapering of Prednisone
Eosinophil count at clinic visit
<750/µl: decrease prednisone dose
to next level
750–1000/µl: hold prednisone dose
at current level
1001–1250/µl: increase prednisone
dose to next level
1251–1500/µl: increase prednisone
dose by two levels
>1500/µl: increase prednisone dose
to baseline controlling level

HES clinical activity at clinic visit
No flare: decrease prednisone dose according
to schedule
Mild clinical flare and eosinophil count <750/µl:
maintain current prednisone dose
Severe clinical flare: increase prednisone dose
to baseline controlling level

Primary end point:
prednisone dose
of ≤10 mg/day
for ≥8 consecutive weeks

Start of prednisone tapering (wk 1)

Safety
follow-up
(3 mo after
last dose)

Weekly step-down options for prednisone dose (mg/day)
60
0 1

50

40

4

30

25

8

20

17.5

12

16

15

12.5

10

20

7.5

5

24

28

2.5

0
32

36

Study Week

B
107 Subjects were screened

85 Underwent randomization (intention-to-treat population)

43 Were assigned to receive
mepolizumab

5 Had violations
1 Did not have HES diagnosis
3 Had unapproved
concomitant medication
1 Did not have stable
prednisone dose
2 Were receiving <20 mg of
prednisone per day at entry

38 Were in the modified
per-protocol population

42 Were assigned to receive
placebo

7 Withdrew
5 Had lack of efficacy
1 Had adverse event
1 Withdrew consent

27 Withdrew
21 Had lack of efficacy
2 Had adverse event
1 Withdrew consent
1 Had disease
progression
2 Had other reasons

36 Completed the study

15 Completed the study

2 Had violations
1 Did not have HES diagnosis
1 Had unapproved
concomitant medication
1 Did not have stable
prednisone dose
1 Had only 0 or 1 dose of
study drug

40 Were in the modified
per-protocol population

Figure 1. Study Design and Enrollment and Follow-up of Patients.
Panel A illustrates the study design and the prednisone tapering algorithm. The dose of prednisone (or equivalent) was adjusted at
1st
weekly clinic visits according to the blood eosinophil
count and
the clinical activityRETAKE
of the hypereosinophilic
syndrome (HES). At the disAUTHOR:
Rothenberg
ICM
2nd
cretion of the investigator, tapering below 20REG
mgF per
day could
dosing, and tapering below
FIGURE:
1 of 2have been achieved through alternate-day
10 mg per day could have been more gradual,
with a decrease in dose of less than 2.5 mg per3rdday per week. Panel B shows the screenCASE
Revised
ing, enrollment, random assignment, and follow-up of patients. Patients
Line could
4-Chave had more than one type of protocol violation.
EMail
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early but received at least two doses of the study
drug entered an open-label extension study evaluating the long-term safety, efficacy, and optimal
dosing frequency of intravenous mepolizumab.
Patients choosing not to continue in the extension
study completed a safety follow-up visit 3 months
after their last dose of study medication.
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(SF-12) (version 2) physical and mental component
summary scores and the Rotterdam Symptom
Checklist.
SAFETY

Safety was assessed with the use of adverse event
reports, laboratory tests (clinical chemical and
hematologic tests and urinalysis), electrocardioCLINICAL EFFICACY
grams, physical examinations, and vital signs reThe primary end point was the reduction of the corded both before and after infusion.
prednisone dose to 10 mg or less per day (or the
equivalent) for 8 or more consecutive weeks. A pred- STATISTICAL ANALYSIS
nisone dose of 10 mg or less per day was consid- We calculated that 84 patients who could be evalered clinically meaningful and a response lasting uated (42 per study group) would be required to
8 weeks was considered durable. All end points provide a statistical power of 90%, at a two-sided
were analyzed with the use of data from the in- significance level of 5%, to detect a difference of
tention-to-treat population (85 patients who pro- 33% between the two study groups in the percentvided written informed consent, were randomly age of patients in whom in the primary end point
assigned to a study drug, and received at least one was reached (assuming the percentage of patients
dose). The primary end point data were confirmed with a prednisone dose of ≤10 mg per day for ≥8
in a modified per-protocol population (78 patients). weeks was 80% in the mepolizumab group and
Protocol violations (by two patients in the placebo 47% in the placebo group). Differences in the ingroup and five in the mepolizumab group) included cidences of the primary end point were tested
a lack of documented history of the hypereosino- using a Cochran–Mantel–Haenszel test, with stratphilic syndrome, use of unapproved concomitant ification according to the prednisone (or the equivmedications, inability to stabilize the prednisone alent) dose (≤30 mg or >30 mg) at baseline, at a
dose within the specified range during screening, 5% two-sided significance level in the intentionand a prednisone dose of less than 20 mg per day to-treat population. In the primary prespecified
at study entry. Data from the patients who violated analysis, odds ratios were also calculated. Relative
the protocol were included in the intention-to-treat risks (without stratification on the basis of predanalysis.
nisone dose at baseline) and hazard ratios (with
Secondary end points were a blood eosinophil stratification) were also calculated in post-hoc
count of less than 600 per microliter for 8 or analyses. The proportional-hazards assumption
more consecutive weeks, the time to treatment was assessed by inspection of the log–log survival
failure (defined as clinical worsening requiring curves.
other therapy for the hypereosinophilic syndrome,
Adverse events were also summarized. A loga prednisone dose of >60 mg per day, or with- rank test was used to compare the time to an addrawal from the study for any reason), a predni- verse event between the two study groups, includsone dose of 7.5 mg or less per day, receipt of no ing data from patients who withdrew from the
prednisone for 1 day or more, the mean daily pred- study.
nisone dose at week 36, and a prednisone dose
An investigator advisory board, including the
of 10 mg or less per day by week 20 and for 8 or authors and the sponsor, designed the study, with
more consecutive weeks. Post hoc exploratory end scientific guidance from the Food and Drug Adpoints included a prednisone dose of 10 mg or less ministration and the European Committee for
per day for 24 or more weeks and the receipt of Proprietary Medicinal Products. The sponsor was
no prednisone during the treatment period, main- responsible for data collection and quality contained until study completion.
trol and held the data but made them available,
We assessed the effects of the study drug on after ensuring confidentiality, to all the authors.
physical or psychological symptoms of the hype- All the authors analyzed and interpreted the data,
reosinophilic syndrome, health status, and limi- wrote the manuscript, made the decision to pubtations of daily living, using the Medical Outcomes lish, and vouch for the completeness and accuracy
Study 12-item Short Form General Health Survey of the data.
1218
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Table 1. Baseline Demographic and Disease Characteristics in the Intention-to-Treat Population.*
Mepolizumab
(N = 43)

Characteristic

Age — yr
47.0±16.2
Male sex — no. (%)
26 (60)
Race or ethnic group — no. (%)†
White
38 (88)
Black
3 (7)
Asian
2 (5)
Arabic or North African
0
Weight — kg
80.9±22.2
Body-mass index‡
27.0±6.4
Prednisone dose — no. (%)
≤30 mg/day
30 (70)
>30 mg/day
13 (30)
Treated for HES within past 5 yr — no. (%)
41 (95)
Most common discontinued treatments for HES — no. (%)
Any
29 (67)
Imatinib mesylate
18 (42)
Interferon alfa
8 (19)
Hydroxyurea
9 (21)
Most common ongoing treatments for HES — no. (%)
Any
34 (79)
Systemic corticosteroids
34 (79)
Interferon alfa
2 (5)
HES duration — yr
4.3±5.6
Age at HES onset — yr
42.7±17.7
Most prevalent HES-related current clinical condition or disorder — no. (%)§
Any
34 (79)
Skin or subcutaneous
16 (37)
Respiratory
19 (44)
Nervous system
9 (21)
Gastrointestinal
8 (19)
Musculoskeletal
6 (14)
Cardiac
5 (12)
Eye
4 (9)
Eosinophil count
Mean — ×10−9/liter
0.336±0.332
Median — ×10−9/liter
0.210
Serum interleukin-5 — pg/ml‖
8.7, 57.0
Serum tryptase — µg/liter**
Mean
5.7±3.5
Median
5.0

Placebo
(N = 42)

All
(N = 85)

49.1±14.4
17 (40)

48.1±15.3
43 (51)

34 (81)
5 (12)
1 (2)
2 (5)
79.7±18.3
27.8±5.8

72 (85)
8 (9)
3 (4)
2 (2)
80.3±20.3
27.4±6.1

30 (71)
12 (29)
40 (95)

60 (71)
25 (29)
81 (95)

0.87

22 (52)
14 (33)
10 (24)
9 (21)

51 (60)
32 (38)
18 (21)
18 (21)

0.16
0.42
0.56
0.96

36 (86)
36 (86)
1 (2)
6.5±9.5
42.7±16.2

70 (82)
70 (82)
3 (4)
5.4±7.8
42.7±16.9

0.42
0.42
0.57
0.20
0.99

36 (86)
24 (57)
16 (38)
9 (21)
7 (17)
7 (17)
5 (12)
3 (7)

70 (82)
40 (47)
35 (41)
18 (21)
15 (18)
13 (15)
10 (12)
7 (8)

0.42
0.07
0.57
0.96
0.81
0.73
0.97
0.72

0.561±0.921
0.195
72.0

0.447±0.694
0.200

0.88¶

8.2±9.8
6.0

6.9±7.3
5.0

0.46¶

P Value
0.52
0.07
0.45

0.79
0.56

0.98

* Plus–minus values are means ±SD. Unless otherwise stated, P values were calculated with the use of a two-sided t-test with pooled variance (for continuous data) or a chi-square test (for categorical data).
† Race or ethnic group was assessed by the investigator at screening. “Asian” consists of East, Southeast, and South Asian.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Patients may have had more than one current clinical condition or disorder related to the hypereosinophilic syndrome (HES).
¶ This P value was calculated with the use of the Wilcoxon rank-sum test.
‖ Serum interleukin-5 levels for all but three patients (two in the mepolizumab group and one in the placebo group) were under the limit of
detection for the assay (7.8 pg/ml). The levels for the three individual patients are reported here.
** Serum tryptase data were available for 78 patients (41 in the mepolizumab group and 37 in the placebo group).
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Table 2. Effects of Treatment on Corticosteroid Use and Eosinophil Counts in the Intention-to-Treat Population.*
Mepolizumab
(N = 43)

End Point

Placebo
(N = 42)

Odds Ratio or Adjusted
Mean Difference
(95% CI)†
P Value

Primary
Prednisone dose of ≤10 mg/day for ≥8 wk — no. (%)
All patients

36 (84)

18 (43)

8.0 (2.7 to 23.8)

<0.001

Patients receiving prednisone dose of ≤30 mg/day at baseline

26/30 (87)

17/30 (57)

5.0 (1.4 to 17.8)

0.01

Patients receiving prednisone dose of >30 mg/day at baseline

10/13 (77)

1/12 (8)

36.7 (3.3 to 412.3)

<0.001

Secondary
Eosinophil count of <600/µl for ≥8 wk — no. (%)
All patients

41 (95)

19 (45)

18.9 (4.7 to 75.2)

<0.001

Patients receiving prednisone dose of ≤30 mg/day at baseline

28/30 (93)

18/30 (60)

9.3 (1.9 to 46.7)

0.002

Patients receiving prednisone dose of >30 mg/day at baseline‡

13/13 (100)

1/12 (8)

<0.001

Prednisone dose of ≤7.5 mg/day for ≥1 day — no. (%)

37 (86)

21 (50)

5.5 (2.0 to 15.0)

<0.001

No prednisone for ≥1 day — no. (%)

34 (79)

10 (24)

12.8 (4.4 to 37.4)

<0.001

Prednisone dose of ≤10 mg/day by wk 20 and for ≥8 wk — no. (%)

33 (77)

16 (38)

6.0 (2.2 to 16.2)

<0.001

−15.7 (−20.8 to −10.6)

<0.001

0.63 (−3.73 to 4.98)

0.78

2.20 (−2.24 to 6.64)

0.33

Daily prednisone dose — mg
At baseline
At wk 36

29.2±1.6

30.6±1.9§

6.2±1.9

21.8±1.9

42.4±1.7

42.5±1.6

1.0±1.6

0.4±1.7

48.3±1.8

43.4±1.5

2.4±1.6

0.2±1.7

SF-12 summary score¶
Physical component
Baseline score
Adjusted change from baseline at wk 36
Mental component
Baseline score
Adjusted change from baseline at wk 36
Exploratory
Prednisone dose of ≤10 mg/day for ≥24 wk — no. (%)

24 (56)

6 (14)

7.8 (2.7 to 23.0)

<0.001

No prednisone during treatment period and untiil study completion — no. (%)

20 (47)

2 (5)

17.7 (3.7 to 83.8)

<0.001

* Plus–minus values are means ±SE. Odds ratios and hazard ratios were adjusted for prednisone dose at baseline (≤30 mg per day vs. >30
mg per day). Hazard ratios are not reported for end points for which the assumption of proportional hazards was not fulfilled.
† The odds ratio is given for categorical variables. For the continuous variables SF-12 scores and daily dose, the adjusted mean difference was
calculated, with the use of analysis of variance, and the adjusted change from baseline at week 36 was calculated with the use of last-observation-carried-forward analysis.
‡ The odds ratio for this subgroup could not be calculated because of the 100% incidence in the mepolizumab group.
§ This value is based on data from 41 patients only, since 1 patient received only one infusion.
¶ The SF-12 (version 2) physical and mental component summary scores were transformed to a mean of 50 and an SD of 10 in the general
U.S. population.25 Higher scores indicate a better state of health and better functioning. Scores were known for 38 patients in the mepolizumab group and 35 in the placebo group.

R e sult s
BASELINE CHARACTERISTICS

Of the 107 patients screened, 85 were randomly
assigned to treatment with mepolizumab (43 patients) or placebo (42 patients). The majority of
patients in the mepolizumab group (36 of 43 [84%])
1220
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completed the trial, as compared with only 15 of
42 (36%) in the placebo group (Fig. 1B). The most
common reason for withdrawal was lack of efficacy (5 of 43 patients [12%] receiving mepolizumab and 21 of 42 [50%] receiving placebo).
There were no significant differences in demographic or disease characteristics between the
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Hazard Ratio
(95% CI)

Relative Risk
(95% CI)

P Value

2.90 (1.59 to 5.26) <0.001

1.95 (1.34 to 2.84)

<0.001

2.39 (1.27 to 4.50)

1.53 (1.09 to 2.16)

0.01

P Value

0.007

9.23 (1.38 to 61.72) <0.001

3.53 (1.94 to 6.45) <0.001

2.11 (1.50 to 2.96)

<0.001

2.27 (1.19 to 4.33)

1.56 (1.14 to 2.12)

0.002

0.01

12.00 (1.84 to 78.37) <0.001
2.70 (1.56 to 4.66) <0.001

1.72 (1.24 to 2.38)

<0.001

3.60 (1.77 to 7.30) <0.001

3.32 (1.89 to 5.83)

<0.001

3.18 (1.70 to 5.96) <0.001

2.01 (1.32 to 3.06)

<0.001

for the modified per-protocol population of 78
patients (hazard ratio, 3.27; 95% CI, 1.73 to 6.18;
P<0.001). A significant difference between the two
study groups was also found for the subgroups of
prednisone dose at baseline, being more pronounced among patients requiring more than
30 mg per day than among those requiring 30 mg
or less per day (Table 2). In the placebo group, the
primary end point was more likely to be reached
among patients who had been receiving 30 mg or
less of prednisone at baseline (17 of 30 patients
[57%]) than among those who had been receiving
more than 30 mg (1 of 12 [8%]). In contrast, in the
mepolizumab group, 26 of the 30 patients (87%)
who had been receiving 30 mg or less of prednisone at baseline were responders, as were 10 of 13
(77%) who had been receiving more than 30 mg.
All secondary and exploratory efficacy end
points significantly favored the use of mepolizumab (P<0.001) (Table 2 and Fig. 2B). Figure 2D
shows the mean prednisone dose used during the
study. (Additional efficacy analyses, with stratification on the basis of achievement of the primary
end point and status of study completion, are presented in Supplementary Appendix 3.)
Blood Eosinophil Counts and Eosinophil-Derived
Neurotoxin Levels

2.74 (1.09 to 6.90)

0.03

3.91 (1.78 to 8.58)

<0.001

9.77 (2.43 to 39.21) <0.001

study groups at the time of randomization (Table 1). Of note, the mean duration of disease was
more than 5 years, and the majority of patients
(82%) reported at least one clinical manifestation
of the hypereosinophilic syndrome.
EFFICACY

Prednisone-Sparing Effects

Overall, for 36 patients (84%) receiving mepolizumab and 18 (43%) receiving placebo, the prednisone dose was reduced to ≤10 mg per day for
≥8 consecutive weeks during the 36-week treatment period (primary end point) (hazard ratio,
2.90; 95% confidence interval [CI], 1.59 to 5.26;
P<0.001) (Table 2 and Fig. 2A). Similar results were
obtained when the primary end point was analyzed

n engl j med 358;12

A blood eosinophil count of less than 600 per
microliter for 8 or more consecutive weeks was
reached in 41 of the 43 patients (95%) receiving
mepolizumab, as compared with 19 of the 42 (45%)
receiving placebo (P<0.001; hazard ratio, 3.53; 95%
CI, 1.94 to 6.45) (Table 2 and Fig. 2C). The difference between the study groups for this end point
was significant in both subgroups of baseline prednisone dose (≤30 mg and >30 mg). Mean serum
eosinophil-derived neurotoxin levels were significantly different between the two study groups at
all time points evaluated (P<0.001, P<0.001, and
P = 0.005 for reductions between the mepolizu
mab group and the placebo group at weeks 12,
24, and 36, respectively) (Fig. 2F).
Time to Treatment Failure

The time to treatment failure (defined as the number of days to clinical worsening requiring other
therapy for the hypereosinophilic syndrome or an
increase in the prednisone dose to >60 mg per
day) was significantly shorter in the placebo group
than in the mepolizumab group (P<0.001 by the
log-rank test). Nine of 43 patients (21%) receiving
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mepolizumab and 29 of 42 (69%) receiving placebo had treatment failure. The median time to
treatment failure in the placebo group was 136.5
days (95% CI, 106 to 199; Fig. 2E); corresponding
data could not be calculated for mepolizumab,
since less than half the patients receiving that drug
had treatment failure.
Health Outcomes

No significant differences between treatments were
observed in the changes from baseline in SF-12
physical and mental component summary scores
(Table 2) or the Rotterdam Symptom Checklist
(Supplementary Appendix 3).
SAFETY

The mean (±SD) duration of exposure to study
drug (defined as the time between the first and
last infusions) was greater in the mepolizumab
group (6.7±1.9 months) than in the placebo group
(4.3±2.6 months) because of a lower withdrawal
rate. Despite the longer exposure to mepolizumab,
adverse events were reported at similar rates in the
two study groups: 40 of 43 patients (93%) receiving
mepolizumab and 41 of 42 (98%) receiving placebo (Table 3). An adverse event considered by the
investigator to be related to the study drug occurred in 16 of 43 patients (37%) in the mepolizumab group and in 12 of 42 (29%) in the placebo
group (Table 3). One patient receiving mepolizumab and four receiving placebo had adverse events
leading to withdrawal; none of these events were
considered by the investigator to be related to study
drug. No clinically relevant trends or major safety concerns emerged from evaluation of the laboratory tests, vital signs, or electrocardiographic
results.
Serious adverse events occurred in seven patients receiving mepolizumab (14 events, including one death) and five patients receiving placebo
(7 events) (Table 3), but none were deemed by the
investigator to be related to the study drug. Serious adverse events in the mepolizumab group were
asthma, clinical flares of the hypereosinophilic
syndrome, pneumonia, renal failure, bronchitis,
cardiac arrest, dehydration, hepatitis, pancreatitis,
pyrexia, rhinitis, and spinal compression fracture.
Serious adverse events in the placebo group were
clinical flares of the hypereosinophilic syndrome,
pneumonia, dysesthesia, eosinophilia, nephrotic
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Figure 2 (facing page). Efficacy of Mepolizumab
Treatment.
Panel A shows the percentage of patients in whom the
prednisone dose was reduced to 10 mg or less per day
(or the equivalent) for 8 or more consecutive weeks
(the primary end point). Panel B shows the percentage
of patients in whom the prednisone dose was reduced
to 10 mg or less per day for 24 or more consecutive
weeks. Panel C shows the percentage of patients in
whom the blood eosinophil count was maintained
at or below 600 per microliter for 8 or more consecutive weeks. Panel D shows the mean prednisone (or
the equivalent) daily dose during the study. The lastobservation-carried-forward (LOCF) data are those
from the second infusion onward. Panel E is a Kaplan–
Meier plot of the time to treatment failure (defined as
clinical worsening requiring other therapy for the hypereosinophilic syndrome, a prednisone dose of >60 mg
per day, or study withdrawal for any reason) in the intention-to-treat population. Panel F shows the mean
serum eosinophil-derived neurotoxin (EDN) values.
The I bars in Panels D and F indicate standard errors.

syndrome, osteonecrosis, and polyneuropathy. An
18-year-old man with severe hypereosinophilic
syndrome and a history of multiple cardiovascular coexisting conditions died 110 days after his
first mepolizumab infusion, and 26 days after his
fourth and last infusion, from a cardiac arrest attributed to dysrhythmia and internal pacemaker–
defibrillator failure. (Supplementary Appendixes
2 and 4 contain additional information about adverse events.)

Dis cus sion
The hypereosinophilic syndrome is a potentially
severe and debilitating multisystem disorder associated with considerable morbidity, in part due
to the side effects of treatments currently used
for it. We report evidence that corticosteroid-sparing is enabled by mepolizumab in patients negative for FIP1L1–PDGFRA with the hypereosinophilic
syndrome. Treatment with prednisone, which
could be discontinued until study completion,
was able to be stopped during the study in almost 50% of patients receiving mepolizumab.
Mepolizumab also was significantly more effective than placebo at stabilizing blood eosinophil counts. These effects are clinically relevant,
given that reducing eosinophil levels is currently
the primary treatment goal for patients with the
hypereosinophilic syndrome and that long-term
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Table 3. Adverse Events Reported during the 36-Week Study.*
Event

Mepolizumab (N = 43)

Placebo (N = 42)

number of patients (percent)
Serious adverse event
Any

7 (16)

5 (12)

Asthma

2 (5)

0

Hypereosinophilic syndrome flare

1 (2)

1 (2)

Pneumonia

1 (2)

1 (2)

Renal failure

2 (5)

0

Bronchitis

1 (2)

0

Cardiac arrest

1 (2)

0

Dehydration

1 (2)

0

Dysesthesia

0

1 (2)

Eosinophilia

0

1 (2)

Hepatitis

1 (2)

0

Nephrotic syndrome

0

1 (2)

Osteonecrosis

0

1 (2)

Pancreatitis

1 (2)

0

Polyneuropathy

0

1 (2)

Pyrexia

1 (2)

0

Rhinitis resulting in hospital admission

1 (2)

0

Spinal compression fracture

1 (2)

0

Adverse event

1224

Any event

40 (93)

41 (98)

Fatigue

13 (30)

11 (26)

Pruritus

12 (28)

9 (21)

Headache

10 (23)

9 (21)

Arthralgia

9 (21)

7 (17)

Nausea

8 (19)

7 (17)

Diarrhea

8 (19)

6 (14)

Cough

5 (12)

8 (19)

Dyspnea

7 (16)

6 (14)

Upper respiratory tract infection

9 (21)

4 (10)

Back pain

5 (12)

6 (14)

Myalgia

8 (19)

3 (7)

Peripheral edema

7 (16)

4 (10)

Sinusitis

5 (12)

6 (14)

Rash

4 (9)

6 (14)

Abdominal pain

4 (9)

5 (12)

Pyrexia

3 (7)

6 (14)

Vomiting

5 (12)

4 (10)

Asthma

5 (12)

3 (7)

Dizziness

5 (12)

3 (7)
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Table 3. (Continued.)
Event

Mepolizumab (N = 43)

Placebo (N = 42)

number of patients (percent)
Nasopharyngitis

4 (9)

4 (10)

Rhinitis

6 (14)

2 (5)

Pharyngolaryngeal pain†

1 (2)

6 (14)

Bronchitis

5 (12)

1 (2)

Chest pain

4 (9)

2 (5)

Clinically significant or unexpected worsening of HES

2 (5)

4 (10)

Pain in extremity‡

1 (2)

5 (12)

Paresthesia

3 (7)

3 (7)

Urticaria

5 (12)

1 (2)

Acne

3 (7)

2 (5)

Contusion

2 (5)

3 (7)

Erythema

3 (7)

2 (5)

Muscle spasms

3 (7)

2 (5)

Facial swelling

2 (5)

3 (7)

Neck pain

1 (2)

3 (7)

Papular rash

1 (2)

3 (7)

Allergic rhinitis

4 (9)

0

Urinary tract infection

1 (2)

3 (7)

Alopecia

3 (7)

0

Epistaxis

3 (7)

0

Productive cough

3 (7)

0

Drug-related adverse event
Any event

16 (37)

12 (29)

Headache

2 (5)

4 (10)

Arthralgia

4 (9)

2 (5)

Fatigue

4 (9)

1 (2)

Peripheral edema

0

4 (10)

Pruritus

2 (5)

2 (5)

Myalgia

2 (5)

2 (5)

Erythema

1 (2)

2 (5)

Rash

1 (2)

2 (5)

Increased γ-glutamyltransferase

2 (5)

0

Cough

0

3 (7)

Dyspnea

0

2 (5)

* Some patients had more than one adverse event. The serious adverse events and adverse events listed were those reported at an incidence of more than 5% per study group. The drug-related adverse events listed (those considered to
be such by the investigator) were those reported at an incidence of more than 4% per study group. No statistical testing was performed on data for drug-related adverse events. For serious adverse events and adverse events, all comparisons were not significant, unless otherwise noted. HES denotes the hypereosinophilic syndrome.
† P = 0.03 for the comparison of the mepolizumab group and the placebo group.
‡ P = 0.047 for the comparison of the mepolizumab group and the placebo group.
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corticosteroid therapy is associated with a range
of undesirable side effects.26-28 Since the corticosteroid threshold associated with clinically significant toxic effects has been established at approximately 7.5 mg per day of prednisone equivalent,27
it is notable that a prednisone dose of 7.5 mg or
less per day in this study was achieved in significantly more patients receiving mepolizumab than
in those receiving placebo.
No significant differences were found between
the two study groups in SF-12 (version 2) assessments, which may reflect the protocol requirements for disease to be clinically stable at baseline and for stability to be maintained in order for
the patient to remain in the trial. As such, the
quality of life, as measured by the SF-12 survey,
did not deteriorate during the study period. In addition, the baseline mental-component summary
score in the mepolizumab group was similar to
that for the general U.S. population,25 indicating
that with treatment, patients did not feel impaired
by their disease, making it difficult to show an
improvement. The study population was composed
of relatively young patients who were negative for
FIP1L1–PDGFRA and had long-standing corticosteroid-responsive hypereosinophilic syndrome. The
corticosteroid-sparing effects observed in our study
suggest that mepolizumab has substantial potential to reduce treatment-related morbidity. Because
this study was limited to patients who were receiving corticosteroid therapy and whose hypereosinophilic syndrome was clinically well controlled,
no recommendations can be inferred regarding
the use of mepolizumab for patients with acute
presentations or who have not yet received corticosteroid therapy. The same holds true for patients
with the hypereosinophilic syndrome that is unresponsive to systemic corticosteroids, as well as
those positive for FIP1L1–PDGFRA.29
Mean serum interleukin-5 values at baseline
were below the limit of detection (7.8 pg per milliliter) in most patients (Table 1). Such normal serum interleukin-5 levels are probably due to corticosteroid-induced suppression, since patients’
symptoms were stabilized by means of corticosteroid therapy before randomization. The efficacy
of mepolizumab in patients with physiologic levels
of interleukin-5 suggests that this agent should
not be reserved for patients with elevated serum
interleukin-5 levels. Our results provide evidence
that endogenous interleukin-5 in these patients
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with the hypereosinophilic syndrome has a critical role in regulating peripheral eosinophilia.
Our study assessed the effects of mepolizumab administered monthly during a 36-week
treatment period, whereas previous studies of
mepolizumab evaluated 12 weeks of treatment.15,17,18,22,30 Several of these studies focused
on the treatment of asthma, showing significant
reductions in blood, sputum, and bronchial eosinophil counts and safety but limited efficacy
as measured by pulmonary-function testing.15-18
Much remains to be learned about the relation
between blood and tissue eosinophilia and clinical response to treatment in patients with asthma and the hypereosinophilic syndrome. Although
the number of patients in our trial was small, the
preliminary findings suggest that the likelihood
of achieving the primary end point with the use
of mepolizumab was high in the patients with current conditions related to the hypereosinophilic
syndrome. The primary end point was reached in
17 of the 19 patients with respiratory disorders,
5 of the 5 with cardiac disorders, 8 of the 8 with
gastrointestinal disorders, 5 of the 6 with musculoskeletal disorders, and 8 of the 9 with nervoussystem disorders, although in only 11 of the 16
patients with skin or subcutaneous manifestations (Table 1, and Supplementary Appendix 5).
In theory, since interleukin-5 potently primes
eosinophils for enhanced responsiveness to activating signals,6 anti–interleukin-5 may be particularly helpful for reducing the eosinophil-mediated
end-organ pathologic characteristics typically associated with the hypereosinophilic syndrome.
Tissue and vascular damage results in part from
the release of granule proteins, and mepolizumab
treatment was associated with significant reductions in eosinophil-derived neurotoxin levels in our
study (Fig. 2F). In addition, the chronic tissue
damage associated with the hypereosinophilic
syndrome is thought to be mediated by eosinophil
infiltration, and mepolizumab probably decreases
tissue eosinophil levels in patients with the syndrome.21,22
Adverse effects were found in the mepolizumab
group. One patient receiving mepolizumab had
a fatal cardiac arrest, which was not considered to
be drug-related by the investigator, who was unaware of the group assignment. Adverse events
considered drug-related by the investigator were
similar between the mepolizumab group and the
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placebo group. This finding is noteworthy, since
the duration of exposure to study drug was approximately 56% longer for mepolizumab than for
placebo, owing to the greater dropout rate (because of lack of efficacy) in the placebo group.
In addition, some adverse events in both groups
may have resulted from prednisone withdrawal
rather than use of the study drug.
An ongoing, open-label extension trial, involving 78 patients from the current trial, will provide
long-term information on potential safety issues,
efficacy assessments, and optimal dosing frequency (see Supplementary Appendix 4 for details). This
trial will help address whether long-term treatment with mepolizumab will durably reduce eosinophil counts while controlling disease.
In conclusion, our study demonstrated that
mepolizumab treatment enabled clinically significant reductions in corticosteroid dose, and often
corticosteroid discontinuation, in patients negative for FIP1L1–PDGFRA who had the hypereosinophilic syndrome. This proof-of-concept study
shows that administration of anti–interleukin-5
antibodies, an eosinophil-specific and targeted
therapy, has a potential clinical benefit.
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